RSRonald R. Salem

Ronald R. Salem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ronald R. Salem has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Novel Treatment for Metastatic Serous Cystadenocarcinoma Using a Microwave Ablation

    by Timothy D. Md Murtha, Joshua Cornman-Homonoff, Rajasekhara Ayyagari, Xuchen Zhang, Ronald R. MBChB Salem

    The incidence of pancreatic cystic neoplasms has grown because of increased detection. Among these lesions, serous cystadenoma was traditionally thought to be universally benign and indolent. However, there is an exceedingly rare malignant variant of serous cystadenoma known as serous cystadenocarcinoma (SCAC) that can exhibit local invasion into adjacent structures, hepatic implants, and metastatic spread to the abdominal viscera. Diagnosis of SCAC can be challenging as it is histologically identical to serous cystadenoma. To better understand this entity, a review of all published accounts of SCAC was performed in which tumor and patient factors were characterized. In addition, we present the case of a 49-year-old woman who was found to have a solitary hepatic metastasis due to SCAC, 11 years after a distal pancreatectomy for serous cystadenoma. She was successfully treated with percutaneous microwave ablation and has no evidence of recurrence 3 years later. This report details the first published account of percutaneous ablation in such a setting. Compared with hepatectomy, hepatic ablation may offer a less invasive but equally effective treatment option in well-selected patients.


  • A Critical Appraisal of the July Effect: Evaluating Complications Following Pancreaticoduodenectomy

    by Timothy D. Murtha, John W. Kunstman, James M. Healy, Peter S. Yoo, Ronald R. Salem


  • Comprehensive Analysis of the Effect of Ketorolac Administration after Pancreaticoduodenectomy

    by John W. Kunstman, Whitney S. Brandt, Sara Abou Azar, Raymond A. Jean, Ronald R. Salem

    Background Outcome improvement is a major goal of pancreatic surgery. Such efforts include decreasing perioperative narcotic use to optimize care and reduce potential contributions to the opioid crisis. Ketorolac, a frequent component of opioid-minimizing recovery pathways, has not been universally adopted over concerns regarding adverse events including anastomotic fidelity, hemorrhage, and renal failure. We examined ketorolac’s effects on pancreatic fistula (PF) formation and related morbidity after pancreaticoduodenectomy (PD). Study Design A retrospective review of consecutive patients undergoing PD from December 2008 to September 2018 was conducted and stratified by receipt of ketorolac during the initial 5 postoperative days. The primary outcome was clinically relevant PF (CR-PF) per international consensus definitions. Secondary outcomes included fistula risk score (FRS)-adjusted CR-PF and cumulative morbidity. Results Of 429 patients, CR-PF occurred in 9.3% (n = 40), and 249 patients received ketorolac before postoperative day 6 (58.0%), with a mean dose of 36.1 ± 22.3 mg/day. CR-PF occurred in 11.2% (n = 28) of patients receiving ketorolac vs 6.7% (n = 12) who did not ( p = 0.12); CR-PF incidence was unrelated to dose. Overall CR-PF incidence did not differ statistically by ketorolac use in the first 5 days postoperatively across FRS categories. Results from multivariable logistic regression models, adjusted for known PF risk factors suggested that ketorolac was not significantly associated with risk of CR-PF (odds ratio [OR] 1.99 [range 0.93 to 4.26], p = 0.08). Operative mortality and major (Clavien ≥ 3) morbidity, including hemorrhage and renal failure, did not differ statistically between groups. Conclusions Ketorolac administration was associated with an acceptable risk of CR-PF and no increase in major morbidity after PD. These data suggest ketorolac can be used in strategies to optimize analgesia and minimize opioid usage.


  • A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors

    by Timothy D. Murtha, Beatrice C. Lupsa, Sachin Majumdar, Dhanpat Jain, Ronald R. Salem


  • Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies

    by Irvin M Modlin, Andrea Frilling, Ronald R Salem, Daniele Alaimo, Panagiotis Drymousis, Harpreet S Wasan, Stephen Callahan, Omar Faiz, Lei Weng, Nancy Teixeira, et al.

    Background: Surgery is the only curative treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the prediction of residual disease/recurrence is limited in the absence of optimal biomarkers. We examined whether a blood-based multianalyte neuroendocrine gene transcript assay (NETest) would define tumor cytoreduction and therapeutic efficacy. Methods: The NETest is a polymerase chain reaction–based analysis of 51 genes. Disease activity is scaled 0–100%; minimal 47%. A total of 35 GEP-NETs in 2 groups were evaluated. I: after surgery (R0, n=15; residual, n=12); II: nonsurgery (n=8: embolization with gel-foam alone [bland: n=3]), transarterial chemoembolization (n=2), and radiofrequency embolization (n=3). Measurement (quantitative real-time-polymerase chain reaction) and chromogranin A (CgA; enzyme-linked immunosorbent assay) were undertaken preoperatively and 1 month after treatment. Results: NETest score was increased in 35 (100%) preoperatively; 14 (40%) had increased CgA (χ2=30, P−8). Resection reduced NETest from 80±5% to 29%±5, (P<.0001). CgA decrease was insignificant (14.3±1.6 U/L to 12.2±1.7 U/L). NETest decreases correlated with diminished tumor volume (R2=0.29, P=0.03). Cytoreduction significantly reduced NETest from 82±3% to 41%±6, P<.0001). CgA was not decreased (21.4±5.5 U/L to 18.4±10.1 U/L). Four (36%) of 11 R0s with increased NETest at 1 month developed positive imaging (sensitivity 100%, specificity 20%). One hundred percent (ablated group) were transcript- and image-positive. Conclusion: Blood NET transcripts delineate surgical resection/cytoreduction and facilitate identification of residual disease. (Work published). Keywords: Blood NET transcripts, NETest, gastroenteropancreatic neuroendocrine tumors


  • Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.

    by Stacey Stein, Edward Samuel James, Xiangyu Cong, Yanhong Deng, Ronald R Salem, Charles Cha, Bryan William Chang, Howard S. Hochster, Indukala Doddamane, Annmarie Boustani, et al.

    395 Background: Toxicities associated with FOLFIRINOX have prompted use of modifications, despite absence of prospective data validating comparable efficacy and improved tolerability. To determine the impact of attenuated doses of irinotecan and bolus 5FU on efficacy and tolerability, we conducted a prospective phase II study of modified FOLFIRINOX in advanced PC. The efficacy of a FOLFIRINOX regimen has not been previously examined in locally advanced PC (LAPC). Previous studies in LAPC have compared chemo vs chemoRT with median OS in the 9-12 mo range (Loehrer et al, Chauffert et al, Hammel et al). Methods: Previously untreated pts with MPC or LAPC received modified FOLFIRINOX with pegylated filgrastim. Irinotecan and bolus FU were reduced by 25%. AEs were compared to historical control (Conroy et al NEJM 2011). Objective RR in MPC was compared to historical control. PFS and OS were calculated for both cohorts. Results: 31 and 44 pts with LAPC and MPC enrolled. Treatment-related grade 3 and 4 AEs were diarrhea (16.2%), neutropenia (12.2%), fatigue (12.2%), thrombocytopenia (9.5%), anemia (5.4%). Neutropenia (p < 0.0001), vomiting (p = 0.001), and fatigue (p = 0.01) were significantly decreased compared to historical control patients. In MPC, the RR (35.1%) was similar to the historical control group (36.3%; p 0.82); median PFS and OS were 6.1 months (95% CI, 5.19 to 8.31) and10.2 months (95% CI, 7.65 to 14.32) respectively. In LAPC, the RR was 17.2% and median PFS and OS were 17.8 mo (95% CI, 11.0 to 23.9) and 26.6 mo (95% CI, 16.7, NA) respectively. 13 pts went on to surgical resection with 10 now alive and 6 without recurrence. We found no significant association between early metabolic response by FDG-PET imaging and PFS and OS. Conclusions: In this first prospective study of modified FOLFIRINOX, the regimen was well tolerated and associated with decreased incidence of AEs compared to historical control of standard FOLFIRINOX. In MPC pts, the efficacy of the modified regimen appear uncompromised. In this first prospective study of a FOLFIRINOX regimen in LAPC, the PFS and OS surpasses that of previously studied regimens in LAPC. Clinical trial information: NCT01523457.

  • Focal hepatic glycogenosis associated with metastatic insulinoma presenting as mass lesions

    by Monika Vyas, Xuchen Zhang, Jon S. Morrow, Dhanpat Jain, Ronald R. Salem, A. Brian West


  • Open Access

    Pancreaticoduodenectomy for locally advanced colon cancer in hereditary nonpolyposis colorectal cancer

    by Rebecca Zhu, Gabriella Grisotti, Ronald R. Salem, Sajid A. Khan

    Hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch syndrome, accounts for 3 % of newly diagnosed cases of colorectal cancer. While a partial or subtotal colectomy is indicated for early stage disease, there is a paucity of data addressing locally advanced disease involving the foregut. We report two patients with hereditary nonpolyposis colorectal cancer presenting with locally advanced colon cancer surgically managed by pancreaticoduodenectomy with en bloc partial colectomy and a review of the literature. Locally advanced colorectal cancer in HNPCC is a rare clinical entity that requires special surgical consideration. Multidisciplinary treatment, including multi-visceral resection, offers the best long-term outcome.